A new publication involving terlipressin, a compound related to lypressin, appeared on November 1, 2026. The study, titled "Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI," was published in Liver International, the official journal of the International Association for the Study of the Liver.
This publication is listed under PubMed ID 42813964. The event record indicates only that the paper has been published and does not include specific findings, results, or conclusions. No efficacy or safety outcomes are described in the available data.
Lypressin itself remains classified as an unapproved research compound. This publication pertains to terlipressin, a related vasopressin analog, and its use alongside albumin treatment in patients with hepatorenal syndrome with acute kidney injury (HRS-AKI).
Readers interested in the broader context of terlipressin and related vasopressin analog research, including lypressin, are encouraged to consult the compound overview for additional background.